Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

iCAD Gains CFDA Approval to Market Brachytherapy Device in China

publication date: Aug 31, 2017

iCAD, a New Hampshire medical device maker, announced CFDA approval of its Xoft Axxent balloon applicators, which are used in Brachytherapy treatment of breast cancer. The devices allow a small radiation source to be placed in the cavity created during a lumpectomy. The low dose radiation affects tissue close to the source, while minimizing harm to more distant tissue. The CFDA approval allows iCAD to market its complete Xoft® Axxent® Electronic Brachytherapy (eBx®) System® as an intraoperative treatment in China for women with early-stage breast cancer. More details....

Stock Symbol: (NSDQ: ICAD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events


China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020